International law firm CMS has advised BrightCure, a start-up developing probiotic-based therapies for urinary tract infections (UTIs), on its seed fundraising and admission to the IndieBio Accelerator, a US-based accelerator for biotechnology companies.
BrightCure’s first products will include a topical cream and an orally delivered supplement. Through its admission into the IndioBio Accelerator, BrightCure will receive $250,000 in seed funding, lab and co-working space, dedicated mentorship and access to a network of IndieBio alumni, investors, biotech entrepreneurs and corporate partners.
BrightCure is also a member of the CMS equIP Life Sciences Programme, a dedicated programme supporting start-ups across biotech, pharmaceuticals, devices and diagnostics, digital health and healthcare. equIP Life Sciences offers members access to mentoring, training and industry introductions as well as discounted legal advice to help accelerate their growth potential.
Theo Godfrey, Corporate partner at CMS UK, comments: “We are delighted to have successfully advised BrightCure on its fundraising and admission to the IndieBio Accelerator, where it will receive the additional support needed to progress to the next level. As a member of our own accelerator programme focussed on start-ups in the life sciences sector, equIP Life Sciences, BrightCure will continue receive our support as the company develops.”
Chiara Heide, Founder of BrightCure, adds: “It has been a great pleasure to work with a top tier law firm like CMS, whose advice is often out of reach for start-ups. Theo and his team have been a great help to us. The CMS equIP Life Sciences Programme has enabled us access to lawyers who understand the needs of a life sciences start-up and the scale of what we’re trying to achieve. With our legal foundations firmly in place, we can now concentrate on the commercial opportunities that will follow our admission to the IndiBio Accelerator.”
Details of BrightCure’s planned products can be found at bcure.co.uk.
